Vikki Tang

Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis.

J. Chiu, R. Epstein, T. Yau, 2013, Asian Pacific journal of cancer prevention : APJCP.

Is There a Role for Unstimulated Thyroglobulin Velocity in Predicting Recurrence in Papillary Thyroid Carcinoma Patients with Detectable Thyroglobulin after Radioiodine Ablation?

J. Chiu, T. Yau, B. Lang, 2012, Annals of surgical oncology.

Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients.

J. Chiu, T. Yau, T. Cheung, 2019, Journal of Clinical Oncology.

Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.

S. Fan, T. Yau, R. Poon, 2014, Gastroenterology.

The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants

Bryan M. Li, J. Chiu, T. Yau, 2021, Advances in Therapy.

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study

Bryan M. Li, J. Chiu, T. Yau, 2021, Cancers.

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

J. Chiu, T. Yau, C. Lo, 2021, Journal for ImmunoTherapy of Cancer.

Thyroid Immune-Related Adverse Events in Cancer Patients Treated with Anti-PD1/Anti-CTLA4 Immune-Checkpoint Inhibitor Combination: Clinical Course and Outcomes.

J. Chiu, T. Yau, T. Cheung, 2021, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Nivolumab/pembrolizumab in Child-Pugh grade B/C patients with advanced HCC.

J. Chiu, T. Yau, T. Cheung, 2021 .

Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy

J. Chiu, T. Yau, A. Kwong, 2019, Postgraduate Medical Journal.